Dr Pedro Rocha speaks to ecancer about the phase II IDeate-Lung01 study.

The study investigates B7-H3–targeted antibody-drug conjugate I-DXd which demonstrated robust central nervous system (CNS) activity in patients with extensive-stage small cell lung cancer (ES-SCLC) and baseline brain metastases.

At the 12 mg/kg dose, I-DXd achieved a CNS objective response rate of 46% overall and 66% in patients with target brain lesions, including high responses in those without prior radiotherapy.

Dr Rocha highlights that safety was manageable and comparable between patients with and without brain metastases, supporting I-DXd’s potential as a promising treatment option for SCLC with CNS involvement.